| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5998427 | WAYLIS THERAP | Androstenones |
Sep, 2013
(10 years ago) | |
| US5846976 | WAYLIS THERAP | Androstenone derivative |
Sep, 2013
(10 years ago) | |
| US5565467 | WAYLIS THERAP | Androstenone derivative |
Nov, 2015
(8 years ago) | |
Avodart is owned by Waylis Therap.
Avodart contains Dutasteride.
Avodart has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Avodart are:
- US5998427
- US5846976
- US5565467
Avodart was authorised for market use on 20 November, 2001.
Avodart is available in capsule;oral dosage forms.
Avodart can be used as method of treating androgen responsive/mediated condition in mammal by admin a safe, effective amount of dutasteride or pharmaceutically acceptable derivative thereof..conditions include benign prostatic hypertrophy, method of inhibiting 5 alpha testosterone reductase enzyme with dutasteride or its derivative and treating androgen responsive/mediated disease including benign prostatic hyperplasia.
The generics of Avodart are possible to be released after 20 November, 2015.
Drugs and Companies using DUTASTERIDE ingredient
Market Authorisation Date: 20 November, 2001
Treatment: Method of inhibiting 5 alpha testosterone reductase enzyme with dutasteride or its derivative and treating androgen responsive/mediated disease including benign prostatic hyperplasia; Method of treati...
Dosage: CAPSULE;ORAL
AVODART family patents
